EL7.AI
StocksMedium•25 March 2026•
1 min read

Alumis Upgraded to Buy Following Positive Phase 3 Psoriasis Drug Data

Key Facts

1Alumis Inc. (ALMS) was upgraded to Buy following strong Phase 3 data for its psoriasis drug, envudeucitinib.
2The drug demonstrated 74% PASI 75 efficacy, comparable to Johnson & Johnson's newly approved Icotyde.
3The company targets an NDA submission for envudeucitinib in the second half of 2026.

Alumis Inc. (ALMS) received a stock rating upgrade to 'Buy' following the release of strong Phase 3 clinical trial data for its psoriasis treatment, envudeucitinib. The drug demonstrated a 74% efficacy rate on the PASI 75 scale, placing it in direct competition with Johnson & Johnson’s recently approved Icotyde. Analysts highlighted the drug's potential to capture significant market share in the oral psoriasis medication space due to its competitive clinical profile. The company has outlined a regulatory roadmap, targeting a New Drug Application (NDA) submission in the second half of 2026. While the long-term timeline for commercialization remains a factor, the clinical success significantly de-risks the company's primary asset. Market participants are also looking forward to additional data readouts expected in 2026 for other potential indications of the drug.